SALIBET OINTMENT 30G

Indications

Approved Uses

Corticosteroid-responsive dermatoses with hyperkeratosis/scaling (e.g., psoriasis and chronic eczematous/dermatitis conditions with thickened, scaly lesions) where a keratolytic plus topical corticosteroid is appropriate.

Dosage & Administration

Dosing by Condition

For hyperkeratotic corticosteroid-responsive dermatoses (including psoriasis and chronic eczematous/dermatitis lesions): apply a thin layer once or twice daily; reassess after about 2 weeks and generally avoid continuous use beyond 2-4 weeks without medical review.

Initial Dose

Apply a thin film to the affected area twice daily (morning and evening).

Maximum Dose

No universally fixed gram/week maximum for this specific combination; limit to the smallest amount needed, avoid large body-surface-area application and occlusion, and reassess if not improved within 2-4 weeks (earlier in children).

Dose Adjustment Notes

Use the lowest effective amount for the shortest duration; reduce frequency (e.g., to once daily or intermittent use) once control is achieved, and avoid large areas, prolonged continuous use, and occlusion-especially in children-due to increased systemic absorption and HPA-axis suppression risk.

How to Take

Clean and dry the affected area, then apply a thin layer to the affected skin and rub in gently, usually once or twice daily as prescribed; wash hands after application (and before if needed), avoid eyes/face/mucous membranes and broken skin, and do not use occlusive dressings unless directed by a clinician.

Side Effects

Common Side Effects

Common: application-site burning/stinging, itching (pruritus), irritation, dryness, erythema. Uncommon: folliculitis, acneiform eruptions, contact dermatitis, hypopigmentation, hypertrichosis, perioral dermatitis, skin atrophy/thinning, striae, telangiectasia. Rare: secondary infection; systemic corticosteroid effects (e.g., HPA-axis suppression/Cushingoid features) with extensive/prolonged/occluded use; salicylism with large-area/prolonged use.

Side Effect Frequency

Common: local burning/stinging, pruritus, irritation, dryness, erythema; Uncommon: folliculitis, acneiform eruptions, contact dermatitis, hypopigmentation, hypertrichosis, perioral dermatitis, skin atrophy/striae/telangiectasia (risk increases with potency, duration, occlusion); Rare: secondary infection and systemic effects (HPA-axis suppression/Cushingoid features) with extensive/prolonged/occluded use; salicylism is rare but possible with large-area/prolonged use of salicylic acid.

Safety & Warnings

Contraindications

Hypersensitivity to betamethasone dipropionate, salicylic acid, or excipients; viral skin infections (e.g., herpes simplex, varicella/vaccinia); untreated bacterial or fungal skin infections; rosacea; perioral dermatitis; acne vulgaris; perianal/genital pruritus; (commonly also listed) cutaneous tuberculosis.

Warnings & Precautions

External use only; avoid eyes/mucosa and do not use as ophthalmic; avoid occlusion unless directed; avoid large areas, prolonged use, and use on thin-skin/intertriginous areas unless directed; monitor for irritation, secondary infection, and signs of systemic steroid effects (especially in children); risk of salicylism increases with large-area use, damaged skin, occlusion, and renal impairment.

Age Restriction

Use is not recommended in children younger than 13 years of age.

Drug Interactions

Drug Interactions

Clinically significant interactions are uncommon with appropriate topical use; avoid combining with other topical irritants/keratolytics on the same area, and be cautious with extensive/occlusive use where systemic absorption could theoretically add to corticosteroid effects or salicylate exposure.

Food Interaction

No known food interactions (not applicable for topical use).

Alcohol Interaction

Safe

Special Populations

Pregnancy

Caution

Breastfeeding

Caution

Elderly

Use with caution; elderly patients have thinner skin and are at higher risk of skin atrophy and systemic absorption. Apply sparingly and for the shortest effective duration.

Kidney Impairment

No specific renal dose adjustment for topical use; use caution in renal impairment by minimizing area/duration and avoiding occlusion due to potential salicylate accumulation if systemic absorption occurs.

Storage & Patient Advice

Missed Dose

Apply when remembered; if it is close to the next scheduled application, skip the missed dose and resume the regular schedule-do not apply extra to make up for it.

Patient Counseling

Apply a thin film to affected areas only once or twice daily as prescribed; avoid eyes/mucosa and avoid use on face, groin, or axillae unless specifically directed; do not use occlusive dressings unless instructed; use the smallest amount for the shortest duration and seek review if not improving within ~1-2 weeks or if needing prolonged therapy; wash hands after application; stop and seek care for worsening irritation, signs of infection, or skin thinning/striae.

Monitoring Requirements

No routine laboratory monitoring for short courses on limited areas; for prolonged, extensive, pediatric use, or use under occlusion, monitor for local adverse effects (atrophy, striae, infection) and consider HPA-axis suppression assessment if clinically indicated.

Pharmacology

Mechanism of Action

Betamethasone dipropionate activates glucocorticoid receptors to reduce inflammatory cytokines, vasodilation, and pruritus; salicylic acid is keratolytic, decreasing corneocyte cohesion to promote desquamation and improve penetration of the corticosteroid through hyperkeratotic skin.

Metabolism

If systemically absorbed: betamethasone dipropionate is hydrolyzed in skin to betamethasone and then undergoes hepatic metabolism; salicylic acid undergoes hepatic conjugation (glycine to salicyluric acid and glucuronidation).

Protein Binding

If systemically absorbed: salicylic acid is ~50-80% albumin-bound in a concentration-dependent manner; betamethasone is protein-bound (class effect), but a single precise percentage should not be asserted for this topical product without product-specific evidence.

Product Information

Available Dosage Forms

Ointment (topical).

Composition per Dose

Each gram of ointment contains: 0.64 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) and 30 mg of salicylic acid.

Skin Condition

Psoriasis, Eczema, Dermatitis

Steroid Potency

Potent

Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.